Your browser doesn't support javascript.
Management of Thrombotic Complications in COVID-19: An Update.
Hajra, Adrija; Mathai, Sheetal Vasundara; Ball, Somedeb; Bandyopadhyay, Dhrubajyoti; Veyseh, Maedeh; Chakraborty, Sandipan; Lavie, Carl J; Aronow, Wilbert S.
  • Hajra A; Jacobi Medical Center/Albert Einstein College of Medicine, 1400 Pelham Pkwy S, The Bronx, NY, 10461, USA. adrija847@gmail.com.
  • Mathai SV; Jacobi Medical Center/Albert Einstein College of Medicine, 1400 Pelham Pkwy S, The Bronx, NY, 10461, USA.
  • Ball S; Texas Tech University Health Sciences Center, Lubbock, TX, USA.
  • Bandyopadhyay D; Icahn School of Medicine at Mount Sinai/Mount Sinai St. Luke's West Hospital, Manhattan, NY, USA.
  • Veyseh M; Jacobi Medical Center/Albert Einstein College of Medicine, 1400 Pelham Pkwy S, The Bronx, NY, 10461, USA.
  • Chakraborty S; Miami Valley Hospital, Dayton, OH, USA.
  • Lavie CJ; John Ochsner Heart and Vascular Institute, Ochsner Clinical School, The University of Queensland School of Medicine, New Orleans, LA, USA.
  • Aronow WS; Westchester Medical Center, New York Medical College, Valhalla, NY, USA.
Drugs ; 80(15): 1553-1562, 2020 Oct.
Article in English | MEDLINE | ID: covidwho-716437
ABSTRACT
Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV­2), is now a global pandemic. This virus primarily affects the respiratory tract and causes lung injury characterized by acute respiratory distress syndrome. Although the pathophysiology of COVID-19 is not yet clear, the most widely accepted mechanism is systemic inflammation. A clinically significant effect of the inflammation is coagulopathy. As a result of this effect, patients are found to have a high risk of venous thromboembolism. Studies have reported a high incidence of thrombotic complications in critically ill patients with COVID-19. In this review, we discuss the most updated evidence on the pathophysiology, diagnosis, and treatment of the coagulopathy of COVID-19. Prophylactic anticoagulation is recommended for all in-patients with COVID-19. Those with a higher risk of developing thromboembolic events or who have already developed venous thromboembolism should be treated with therapeutic anticoagulation. We also discuss post-discharge prophylaxis for high-risk patients and some newly proposed treatments for the hypercoagulability that could improve the outcomes of the affected patients.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Pneumonia, Viral / Thrombosis / Coronavirus Infections / Venous Thromboembolism Type of study: Observational study / Prognostic study Topics: Long Covid Limits: Humans Language: English Journal: Drugs Year: 2020 Document Type: Article Affiliation country: S40265-020-01377-x

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Pneumonia, Viral / Thrombosis / Coronavirus Infections / Venous Thromboembolism Type of study: Observational study / Prognostic study Topics: Long Covid Limits: Humans Language: English Journal: Drugs Year: 2020 Document Type: Article Affiliation country: S40265-020-01377-x